AU2001280778B2 - Non-sedating barbiturate compounds as neuroprotective agents - Google Patents

Non-sedating barbiturate compounds as neuroprotective agents Download PDF

Info

Publication number
AU2001280778B2
AU2001280778B2 AU2001280778A AU2001280778A AU2001280778B2 AU 2001280778 B2 AU2001280778 B2 AU 2001280778B2 AU 2001280778 A AU2001280778 A AU 2001280778A AU 2001280778 A AU2001280778 A AU 2001280778A AU 2001280778 B2 AU2001280778 B2 AU 2001280778B2
Authority
AU
Australia
Prior art keywords
lower alkyl
substituted
phenyl
compound
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001280778A
Other languages
English (en)
Other versions
AU2001280778A1 (en
Inventor
Barrie Levitt
Daniel A. Moros
Avraham Yacobi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taro Pharmaceutical Industries Ltd
Original Assignee
Taro Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taro Pharmaceutical Industries Ltd filed Critical Taro Pharmaceutical Industries Ltd
Publication of AU2001280778A1 publication Critical patent/AU2001280778A1/en
Application granted granted Critical
Publication of AU2001280778B2 publication Critical patent/AU2001280778B2/en
Priority to AU2004229086A priority Critical patent/AU2004229086C1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2001280778A 2000-07-26 2001-07-26 Non-sedating barbiturate compounds as neuroprotective agents Ceased AU2001280778B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2004229086A AU2004229086C1 (en) 2000-07-26 2004-11-15 Non-sedating barbiturate compounds as neuroprotective agents

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22167200P 2000-07-26 2000-07-26
US60/221,672 2000-07-26
PCT/US2001/023420 WO2002007729A1 (en) 2000-07-26 2001-07-26 Non-sedating barbiturate compounds as neuroprotective agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2004229086A Division AU2004229086C1 (en) 2000-07-26 2004-11-15 Non-sedating barbiturate compounds as neuroprotective agents

Publications (2)

Publication Number Publication Date
AU2001280778A1 AU2001280778A1 (en) 2002-05-02
AU2001280778B2 true AU2001280778B2 (en) 2004-09-02

Family

ID=22828824

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001280778A Ceased AU2001280778B2 (en) 2000-07-26 2001-07-26 Non-sedating barbiturate compounds as neuroprotective agents
AU8077801A Pending AU8077801A (en) 2000-07-26 2001-07-26 Non-sedating barbiturate compounds as neuroprotective agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU8077801A Pending AU8077801A (en) 2000-07-26 2001-07-26 Non-sedating barbiturate compounds as neuroprotective agents

Country Status (13)

Country Link
EP (1) EP1311270B1 (enExample)
JP (1) JP5047442B2 (enExample)
CN (2) CN100522172C (enExample)
AT (1) ATE383159T1 (enExample)
AU (2) AU2001280778B2 (enExample)
BR (1) BR0112775A (enExample)
CA (1) CA2416535C (enExample)
DE (1) DE60132337T2 (enExample)
ES (1) ES2300349T3 (enExample)
IL (3) IL154060A0 (enExample)
MX (1) MXPA03000824A (enExample)
PT (1) PT1311270E (enExample)
WO (1) WO2002007729A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093820A (en) 1997-10-02 2000-07-25 Taro Pharmaceutical Industries Ltd. Method and reagents for N-alkylating ureides
US7683071B2 (en) 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US6939873B2 (en) 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
WO2002007729A1 (en) * 2000-07-26 2002-01-31 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US6756379B2 (en) 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
EP1485101A4 (en) * 2002-01-30 2006-04-12 Taro Pharma Ind NON-SURFACTANT BARBITIC ACID DERIVATIVES
ATE546136T1 (de) 2002-10-11 2012-03-15 Baxter Int Kardioprotektions- und neuroprotektionsverfahren durch intravenöse verabreichung von halogenierten flüchtigen narkosemitteln
JP4739760B2 (ja) * 2002-12-11 2011-08-03 タロー・ファーマシューティカル・インダストリーズ・リミテッド バルビツール酸誘導体を使用する運動障害の治療方法
EP1625848A1 (en) * 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid
RU2370266C2 (ru) * 2007-12-21 2009-10-20 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ общего обезболивания
EP2755945A1 (en) * 2011-09-12 2014-07-23 Council of Scientific & Industrial Research ARYLATED beta-DICARBONYL COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF
CN102863579B (zh) * 2012-09-14 2014-02-05 东南大学 一种巴比妥酸螯合树脂及其制备方法和应用
US11016084B2 (en) 2015-10-05 2021-05-25 The University Of North Carolina At Chapel Hill Decoding methods for multiplexing assays and associated fluidic devices, kits, and solid supports

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002007729A1 (en) * 2000-07-26 2002-01-31 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL69722A (en) * 1983-09-14 1986-09-30 Taro Pharma Ind Oxopyrimidine derivatives and pharmaceutical compositions containing them
US4833148A (en) * 1987-04-09 1989-05-23 Washington University Method of using alkenyl- or alkynyl-substituted thiobarbiturates to reduce neurotoxic injury
US5474990A (en) * 1989-10-20 1995-12-12 Olney; John W. Barbiturates as safening agents in conjunction with NMDA antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002007729A1 (en) * 2000-07-26 2002-01-31 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents

Also Published As

Publication number Publication date
CA2416535C (en) 2010-11-16
IL165017A0 (en) 2005-12-18
JP2004517808A (ja) 2004-06-17
WO2002007729A1 (en) 2002-01-31
IL154060A (en) 2013-05-30
BR0112775A (pt) 2003-12-30
ES2300349T3 (es) 2008-06-16
AU8077801A (en) 2002-02-05
CN100522172C (zh) 2009-08-05
DE60132337D1 (de) 2008-02-21
PT1311270E (pt) 2008-04-15
EP1311270A4 (en) 2006-04-12
CA2416535A1 (en) 2002-01-31
JP5047442B2 (ja) 2012-10-10
HK1100814A1 (en) 2007-09-28
MXPA03000824A (es) 2004-11-01
IL154060A0 (en) 2003-07-31
ATE383159T1 (de) 2008-01-15
CN1872067A (zh) 2006-12-06
DE60132337T2 (de) 2009-02-12
WO2002007729A9 (en) 2002-08-08
EP1311270A1 (en) 2003-05-21
CN1329032C (zh) 2007-08-01
CN1461219A (zh) 2003-12-10
EP1311270B1 (en) 2008-01-09

Similar Documents

Publication Publication Date Title
US8158639B2 (en) Non-sedating barbiturate compounds as neuroprotective agents
EP1311270B1 (en) Non-sedating barbiturate compounds as neuroprotective agents
US11633385B2 (en) Combination compositions for treatment of cancer
AU2001280778A1 (en) Non-sedating barbiturate compounds as neuroprotective agents
EP4054620B1 (en) Semaglutide in the treatment of alzheimer's dementia
US10434100B2 (en) Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes
MXPA05004180A (es) Metodos de uso y composiciones que contiene un inhibidor de jnk para el tratamiento, prevencion, manejo y/o modificacion del dolor.
AU757541B2 (en) Use of adenosine agonists in cancer therapy
AU2004229086C1 (en) Non-sedating barbiturate compounds as neuroprotective agents
US20050130990A1 (en) Nicotinic receptor agonists for the treatment of inflammatory diseases
AU2007200460B2 (en) Non-sedating barbiturate compounds as neuroprotective agents
EP1905441A2 (en) Non-sedating barbiturate compounds as neuroprotective agents
KR20190087572A (ko) 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
HK1100814B (en) Use Of A Salt Of Diphenyl Barbituric Acid In Preparing Neuroprotective Agents
US20100210596A1 (en) Use of aminopyrimidine compounds in the treatment of immune disorders
HK40075453A (en) Semaglutide in the treatment of alzheimer's dementia

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired